Rhinitis Allergic Clinical Trial
Official title:
Evaluation of Efficacy of Dellegra® Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen Exposure in Japanese Population. Open Label Study
Primary Objective:
To collect and analyze clinical data of Allergic Rhinitis patients' Total Nasal Symptom
Score (TNSS) change after Dellegra internal use under high density pure Japanese cedar
pollen exposure.
Secondary Objective:
To collect and analyze clinical data of Allergic Rhinitis patients' change in Total Symptom
Score (TSS) and amount of nasal discharge, safety, and overall patients' impression about
efficacy of Dellegra after Dellegra internal use under high density pure Japanese cedar
pollen exposure.
It will be 8 days at minimum and up to 17 days depending on screening visit and post-treatment observation allowances. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03317015 -
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
|
Phase 3 | |
| Completed |
NCT02401191 -
A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00380705 -
Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)
|
Phase 4 | |
| Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 | |
| Not yet recruiting |
NCT05720455 -
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
|
Phase 4 | |
| Completed |
NCT00446186 -
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
|
Phase 2 |